Business Context and Reporting Period
This Form 8-K Current Report was filed by Silo Pharma, Inc. on April 6, 2021. The filing discloses the entry into a Material Definitive Agreement, specifically a Sublicense Agreement with AIkido Pharma, Inc., effective April 6, 2021.
Key Financial Metrics
The filing does not provide standard financial statements, revenue, profit, cash flow, or debt metrics. The financial terms of the disclosed agreement are as follows:
- Upfront License Fee: Mid five figures.
- Sales-Based Royalties: Low to mid single-digit percentages (tiered based on net revenues).
- Total Milestone Payments: Up to $1.9 million.
Material Changes
The primary material change is the execution of the Sublicense Agreement granting AIkido Pharma, Inc. an exclusive worldwide sublicense. This agreement covers:
- Development, manufacture, and commercialization of "Licensed Products."
- Use of an invention regarding "Central nervous system-homing peptides in vivo" for investigating and treating multiple sclerosis and other neuroinflammatory pathologies.
- Practice of certain patent rights for the therapeutic treatment of neuroinflammatory disease in cancer patients.
Outlook, Risks, and Unusual Items
Agreement Duration: The agreement continues on a product-by-product and country-by-country basis until the later of patent expiration, regulatory exclusivity expiration, or 10 years after the first commercial sale. It expires 15 years after the Effective Date in countries with no patent rights, data protection, or commercial sales.
Confidentiality: Certain portions of the Sublicense Agreement exhibit were omitted as confidential and competitively harmful.
Management Commentary: The filing references a press release issued on April 7, 2021, announcing the agreement, but does not include additional management commentary within the text of this report.
Investor Verification Checklist
- Verify the exact amount of the "mid five figures" upfront payment in the full text of Exhibit 10.1.
- Review the specific royalty tiers and net revenue thresholds in the Sublicense Agreement.
- Confirm the specific milestones triggering the up to $1.9 million in payments.
- Assess the status of the underlying Master License Agreement with the University of Maryland, Baltimore.
- Review the full press release (Exhibit 99.1) for additional strategic context.